Kissei Pharmaceutical Obtains Manufacturing Approval for URIEF Capsule, Benign Prosatic Hypertrophy Drug.Tokyo, Japan, Jan 24, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Kissei Pharmaceutical announced on January 23 that it has received approval from the Ministry of Health, Labor and Welfare to manufacture URIEF Capsule 2mg/4mg, its proprietary agent for treating benign prostatic hypertrophy Benign prostatic hypertrophy (BPH) Benign prostatic hypertrophy is an enlargement of the prostate that is not cancerous. However, it may cause problems with urinating or other symptoms. (BPH BPH abbr. benign prostatic hyperplasia BPH Benign prostatic hypertrophy, a very common noncancerous cause of prostatic enlargement in older men. ). URIEF Capsule (silodosin), a selective alpha-1A receptor antagonist, is indicated for the treatment of urinary disturbance associated with BPH. After listing the drug on the NHI NHI abbr. National Health Insurance drug price list, Kissei Pharmaceutical and Daiichi Pharmaceutical will jointly promote the agent. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion